Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED ...

The RhodoLED XL is approved by the FDA in combination with Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate ...

The RhodoLED XL is approved by the FDA in combination with Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate ...

What Are Actinic Keratoses? Actinic keratoses (AKs) are a common skin condition characterized by rough, red, scaly patches, crusts, or sores on the top layer of skin (see Figures 1 & 2).

The RhodoLED XL is approved by the FDA in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate ...

Once daily, 1 week AK lesion reduction from baseline: 28.8 Complete clearance: 0 AK lesion reduction from baseline: 62.6 Complete clearance: 18.1 <0.001 <0.001 In 5-FU group application, site ...

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a ...

Enhance your proficiency in diagnosing and managing actinic keratosis with S. Karger Publishers' interactive course tailored for primary care professionals. In just 30 minutes, you will gain ...

(Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will be ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...